163 related articles for article (PubMed ID: 36924348)
1. Acneiform eruption induced by molecularly targeted agents in antineoplastic therapy: A review.
Yuan C; Wang B
J Cosmet Dermatol; 2023 Aug; 22(8):2150-2157. PubMed ID: 36924348
[TBL] [Abstract][Full Text] [Related]
2. Acneiform eruption induced by cetuximab.
Cotena C; Gisondi P; Colato C; Girolomoni G
Acta Dermatovenerol Croat; 2007; 15(4):246-8. PubMed ID: 18093454
[TBL] [Abstract][Full Text] [Related]
3. Targeted tumour therapy induced papulopustular rash and other dermatologic side effects: a retrospective study.
Yalici-Armagan B; Ayanoglu BT; Demirdag HG
Cutan Ocul Toxicol; 2019 Sep; 38(3):261-266. PubMed ID: 31010330
[No Abstract] [Full Text] [Related]
4. Prevention and management of acneiform rash associated with EGFR inhibitor therapy: A systematic review and meta-analysis.
Gorji M; Joseph J; Pavlakis N; Smith SD
Asia Pac J Clin Oncol; 2022 Dec; 18(6):526-539. PubMed ID: 35352492
[TBL] [Abstract][Full Text] [Related]
5. An Analysis of Risk Factors for the Development of Acneiform Eruptions in Patients on Monoclonal Antibody Epidermal Growth Factor Receptor Inhibitors.
Bierbrier R; D'Aguanno K; Oliel S; Zeng Y; Esfahani K; Pehr K
J Cutan Med Surg; 2023 Nov; 27(6):614-620. PubMed ID: 37942582
[TBL] [Abstract][Full Text] [Related]
6. Survey of Oncologists and Dermatologists in Canada on the Management of Acneiform Eruptions Induced by Epidermal Growth Factor Receptor Inhibitors.
Bierbrier R; Esfahani K; Pehr K
J Cutan Med Surg; 2022; 26(6):624-625. PubMed ID: 35980317
[No Abstract] [Full Text] [Related]
7. Acneiform eruptions with combination targeted cancer therapy in colorectal cancer patients.
Ibraheim MK; Lo J; Gupta R; Parseghian C; Patel AB
Support Care Cancer; 2022 Oct; 30(10):8051-8058. PubMed ID: 35771289
[TBL] [Abstract][Full Text] [Related]
8. Efficacy, tolerability and impact on quality of life of clindamycin phosphate and benzoyl peroxide for the treatment of cetuximab-associated acneiform eruption in patients with metastatic colorectal cancer.
Vaccaro M; Guarneri F; Borgia F; Pollicino A; Altavilla G; Cannavò SP
J Dermatolog Treat; 2016; 27(2):148-52. PubMed ID: 26313697
[TBL] [Abstract][Full Text] [Related]
9. Management of Dermatologic Complications of Lung Cancer Therapies.
Pugliese SB; Neal JW; Kwong BY
Curr Treat Options Oncol; 2015 Oct; 16(10):50. PubMed ID: 26338208
[TBL] [Abstract][Full Text] [Related]
10. Xerosis and pruritus as major EGFRI-associated adverse events.
Clabbers JMK; Boers-Doets CB; Gelderblom H; Stijnen T; Lacouture ME; van der Hoeven KJM; Kaptein AA
Support Care Cancer; 2016 Feb; 24(2):513-521. PubMed ID: 26111953
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous toxicities of antineoplastic agents: data from a large cohort of Greek patients.
Nikolaou V; Voudouri D; Tsironis G; Charpidou A; Stamoulis G; Triantafyllopoulou I; Panoutsopoulou I; Xidakis E; Bamias A; Samantas E; Aravantinos G; Gogas H; Rigopoulos D; Syrigos K; Stratigos A
Support Care Cancer; 2019 Dec; 27(12):4535-4542. PubMed ID: 30919155
[TBL] [Abstract][Full Text] [Related]
12. Severe EGFR inhibitor-induced acneiform eruption responding to dapsone.
Beshay A; Petersen M; Rhoads JLW
Dermatol Online J; 2021 Jul; 27(7):. PubMed ID: 34391331
[TBL] [Abstract][Full Text] [Related]
13. Reader Comment Regarding "Survey of Oncologists and Dermatologists in Canada on the Management of Acneiform Eruptions Induced by Epidermal Growth Factor Receptor Inhibitors".
Fournier C; Sauder MB
J Cutan Med Surg; 2023; 27(3):294. PubMed ID: 36927192
[No Abstract] [Full Text] [Related]
14. Chronic cutaneous lupus erythematosus presenting as atypical acneiform and comedonal plaque: case report and literature review.
Vieira ML; Marques ERMC; Leda YLA; Noriega LF; Bet DL; Pereira GAAM
Lupus; 2018 Apr; 27(5):853-857. PubMed ID: 28857716
[TBL] [Abstract][Full Text] [Related]
15. EGFR inhibitors: clinical aspects, risk factors and biomarkers for acneiform eruptions and other mucosal and cutaneous adverse effects.
Recuero JK; Fitz JR; Pereira AA; Bonamigo RR
An Bras Dermatol; 2023; 98(4):429-439. PubMed ID: 36990917
[TBL] [Abstract][Full Text] [Related]
16. Dermatological side effects of targeted antineoplastic therapies: a prospective study.
Agirgol S; Çaytemel C; Pilanci KN
Cutan Ocul Toxicol; 2020 Dec; 39(4):380-384. PubMed ID: 33028137
[TBL] [Abstract][Full Text] [Related]
17. [Cutaneous toxicities].
Matsumoto K; Saida T
Gan To Kagaku Ryoho; 2008 Oct; 35(10):1645-8. PubMed ID: 18931563
[TBL] [Abstract][Full Text] [Related]
18. Cetuximab-induced cutaneous toxicity.
Tomková H; Kohoutek M; Zábojníková M; Pospísková M; Ostrízková L; Gharibyar M
J Eur Acad Dermatol Venereol; 2010 Jun; 24(6):692-6. PubMed ID: 19925598
[TBL] [Abstract][Full Text] [Related]
19. A case of successfully treated recalcitrant EGFR inhibitor-induced acneiform eruption following non-ablative fractional laser.
Choi JW; Kim TI; Jeong KH; Shin MK
Dermatol Ther; 2016 Jul; 29(4):252-4. PubMed ID: 27146102
[TBL] [Abstract][Full Text] [Related]
20. A systematic review of oral retinoids for treatment of acneiform eruptions induced by epidermal growth factor receptor inhibitors.
Bierbrier R; Lam M; Pehr K
Dermatol Ther; 2022 May; 35(5):e15412. PubMed ID: 35220635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
